Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $37.2 million.

  • Kymera Therapeutics' Current Deferred Revenue rose 8595.69% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year increase of 8595.69%. This contributed to the annual value of $13.6 million for FY2024, which is 7515.87% down from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Current Deferred Revenue is $37.2 million, which was up 8595.69% from $40.0 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Current Deferred Revenue ranged from a high of $152.6 million in Q1 2021 and a low of $11.5 million during Q1 2025
  • In the last 5 years, Kymera Therapeutics' Current Deferred Revenue had a median value of $54.7 million in 2023 and averaged $63.8 million.
  • Over the last 5 years, Kymera Therapeutics' Current Deferred Revenue had its largest YoY gain of 8595.69% in 2025, and its largest YoY loss of 7526.4% in 2025.
  • Over the past 5 years, Kymera Therapeutics' Current Deferred Revenue (Quarter) stood at $101.0 million in 2021, then tumbled by 37.39% to $63.3 million in 2022, then dropped by 13.61% to $54.7 million in 2023, then tumbled by 75.16% to $13.6 million in 2024, then skyrocketed by 174.28% to $37.2 million in 2025.
  • Its Current Deferred Revenue was $37.2 million in Q3 2025, compared to $40.0 million in Q2 2025 and $11.5 million in Q1 2025.